Literature DB >> 1633836

Sustained high plasma 5-aminolaevulinic acid concentration in a volunteer: no porphyric symptoms.

P Mustajoki1, K Timonen, A Gorchein, A M Seppäläinen, E Matikainen, R Tenhunen.   

Abstract

The pathogenesis of the acute porphyric attack is not known. One hypothesis is that porphyrin precursors, especially 5-aminolaevulinic acid (ALA), are toxic for neuronal tissue. This was tested by infusing ALA in a male volunteer after a loading dose at a rate of 50-80 mg h-1 for 92.5 h. During the experiment plasma ALA concentration was 9-11 mumol 1-l and porphobilinogen concentration 3-6 mumol 1-l which are the levels seen during acute attacks. Urinary excretion of these porphyrin precursors was also markedly increased. ALA infusion caused no subjective symptoms and no change in pulse rate, blood pressure, or autonomic nerve function or conduction velocity of peripheral nerves. Photosensitivity was not demonstrable. It is concluded that sustained high plasma ALA concentration does not cause porphyria-like symptoms.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1633836     DOI: 10.1111/j.1365-2362.1992.tb01482.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  9 in total

Review 1.  Heme biosynthesis and the porphyrias.

Authors:  John D Phillips
Journal:  Mol Genet Metab       Date:  2019-04-22       Impact factor: 4.797

2.  Motor neuropathy in porphobilinogen deaminase-deficient mice imitates the peripheral neuropathy of human acute porphyria.

Authors:  R L Lindberg; R Martini; M Baumgartner; B Erne; J Borg; J Zielasek; K Ricker; A Steck; K V Toyka; U A Meyer
Journal:  J Clin Invest       Date:  1999-04       Impact factor: 14.808

3.  Photosensitisation and photodynamic therapy of oesophageal, duodenal, and colorectal tumours using 5 aminolaevulinic acid induced protoporphyrin IX--a pilot study.

Authors:  J Regula; A J MacRobert; A Gorchein; G A Buonaccorsi; S M Thorpe; G M Spencer; A R Hatfield; S G Bown
Journal:  Gut       Date:  1995-01       Impact factor: 23.059

4.  Biochemical characterization of porphobilinogen deaminase-deficient mice during phenobarbital induction of heme synthesis and the effect of enzyme replacement.

Authors:  Annika Johansson; Christer Möller; Jens Fogh; Pauline Harper
Journal:  Mol Med       Date:  2003 Sep-Dec       Impact factor: 6.354

5.  Heme deficiency in Alzheimer's disease: a possible connection to porphyria.

Authors:  Barney E Dwyer; Meghan L Stone; Xiongwei Zhu; George Perry; Mark A Smith
Journal:  J Biomed Biotechnol       Date:  2006

6.  Preanesthetic severe postural hypotension following 5-aminolevulinic acid pretreatment in patients for photodynamic diagnosis-assisted urological surgery.

Authors:  Tohru Shiratori; Kunihisa Hotta; Masaaki Satoh; Chiaki Kiuchi; Noriyuki Ogawa; Takayuki Kamigaito
Journal:  JA Clin Rep       Date:  2019-11-09

Review 7.  Therapy Follows Diagnosis: Old and New Approaches for the Treatment of Acute Porphyrias, What We Know and What We Should Know.

Authors:  Petro E Petrides
Journal:  Diagnostics (Basel)       Date:  2022-07-03

8.  Photodynamic therapy using 5-aminolaevulinic acid for experimental pancreatic cancer--prolonged animal survival.

Authors:  J Regula; B Ravi; J Bedwell; A J MacRobert; S G Bown
Journal:  Br J Cancer       Date:  1994-08       Impact factor: 7.640

9.  Oral versus intravenous administration of 5-aminolaevulinic acid for photodynamic therapy.

Authors:  C S Loh; A J MacRobert; J Bedwell; J Regula; N Krasner; S G Bown
Journal:  Br J Cancer       Date:  1993-07       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.